- Zelira Therapeutics (ZLD) has launched its proprietary cannabinoid medicine, Zenivol, in Australia
- The company has received approval from the Therapeutic Goods Administration’s (TGA) Special Access Scheme to launch the treatment
- Zenivol is for patients with chronic insomnia and will be available through Zelira’s distribution partner, Health House
- This announcement follows a successful clinical trial conducted by the University of Western Australia
- Zelira is on track to launch five new products across global markets in 2020
- Company shares are up 10 per cent on the market this morning, trading for 6.6 cents per share
Zelira Therapeutics (ZLD) proprietary cannabinoid medicine, Zenivol, can now be prescribed to patients in Australia.
This comes after the company received the Therapeutic Goods Administration’s (TGA) Special Access Scheme approval for the treatment.
Zenivol is for patients with chronic insomnia and will be available through Zelira’s distribution partner, Health House.
The company recently completed a world-first clinical trial “powered to show statistical significance through a randomised, double-blind, cross-over designed phase 2A clinical study in patients suffering from chronic insomnia treated with Zenivo.”
Results from this clinical trial, which was conducted at the University of Western Australia’s (UWA) Centre for Sleep Science, show Zenivol is a safe and effective therapy for chronic insomnia.
The trial indicated patients who were treated with the product slept longer, went to sleep faster and went back to sleep sooner after waking. Patients also said they felt less stressed, less fatigued and improved overall functioning.
Managing Director Richard Hopkins is pleased to launch Zenivol in the Australian market.
“Zelira’s ability to launch Zenivol just five months after completing a clinical trial highlights the speed we can bring products to market using our unique ‘Launch Learn and Develop’ strategy,” he said.
“I would like to acknowledge the fantastic efforts of the Zelira team and our collaborators from the University of Western Australia who conducted the clinical trial, all of whom have made this launch possible,” Richard added.
Zelira is on track to launch five new products across global markets in 2020.
Company shares are up 10 per cent on the market this morning, trading for 6.6 cents per share at 11:47 am AEST.